Nanovibronix (NAOV) Competitors

Co-Diagnostics (NASDAQ:CODX) and Nanovibronix (NASDAQ:NAOV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Does the media prefer CODX or NAOV?

In the previous week, Co-Diagnostics had 1 more articles in the media than Nanovibronix. MarketBeat recorded 2 mentions for Co-Diagnostics and 1 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.00 beat Co-Diagnostics' score of -0.33 indicating that Nanovibronix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, CODX or NAOV?

Co-Diagnostics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Which has higher valuation & earnings, CODX or NAOV?

Nanovibronix has lower revenue, but higher earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$3.91M	2.12	-$37.64M	-$1.17	-0.21
Nanovibronix	$2.56M	0.84	-$3.70M	-$13.53	-0.06

Do analysts recommend CODX or NAOV?

Co-Diagnostics currently has a consensus target price of $5.50, suggesting a potential upside of 2,129.43%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, research analysts clearly believe Co-Diagnostics is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Nanovibronix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is CODX or NAOV more profitable?

Nanovibronix has a net margin of -210.82% compared to Co-Diagnostics' net margin of -1,025.45%. Nanovibronix's return on equity of -54.73% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-1,025.45%	-60.16%	-52.69%
Nanovibronix	-210.82%	-54.73%	-38.63%

Do insiders and institutionals hold more shares of CODX or NAOV?

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 8.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 6.3% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Co-Diagnostics beats Nanovibronix on 9 of the 17 factors compared between the two stocks.